Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parsol 1789

This article was originally published in The Tan Sheet

Executive Summary

FDA has "tentatively concluded that [Parsol 1789] cannot be included in the [OTC sunscreen drug products] monograph at this time," Jeanne Rippere of FDA's Office of OTC Drug Evaluation told a Nov. 16 FDA Compliance Seminar in Washington, D.C. Although Rippere noted that the agency is still evaluating additional data, including data submitted by Givaudan-Roure ("The Tan Sheet" Sept. 26, p. 16), FDA "felt [it] needed to know more about Parsol and its interaction with other sunscreens with which it might be combined under the OTC monograph system." Explaining FDA's cautious approach to Parsol 1789, Rippere also cited "reports of increased incidence of sensitization from dibenzoylmethanes in Europe," "adverse drug experiences" and "recent problems" associated with Allergan Herbert's Photoplex, which the company withdrew from the U.S. last year due to marketing considerations
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel